ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
A novel mechanism of chlorogenic acid against type 2 diabetes-induced diabetic retinopathy: suppressing ferroptosis via NRF2/xCT/GPX4 and STAT3 signaling.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
Abstract
Diabetic retinopathy (DR) is a common microvascular complication of type 2 diabetes (T2D), driven by hyperglycemia-induced oxidative stress, ferroptosis, and inflammatory signaling. Here, we demonstrate that chlorogenic acid (CGA) ameliorates T2D and DR by simultaneously modulating the NRF2/xCT/GPX4 antioxidant pathway and the p-STAT3/xCT/GPX4 inflammatory-ferroptosis axis. High-fat diet (HFD) combined with streptozotocin (STZ)-induced T2D mice and high-glucose (HG)-stimulated human retinal microvascular endothelial cells (HRMECs) were used to evaluate the effects of CGA in vivo and in vitro. Network pharmacology, molecular docking, Western blotting, immunofluorescence, Seahorse metabolic assays, and site-directed mutagenesis were employed to investigate the underlying molecular mechanisms. CGA treatment significantly improved systemic metabolic parameters, including fasting blood glucose, HbA1c, and insulin sensitivity, while reducing anxiety-like behavior in T2D mice. Histological analyses revealed that CGA alleviated retinal structural abnormalities and decreased lipid droplet accumulation. Mechanistically, CGA activated NRF2/xCT/GPX4 signaling to enhance antioxidant defenses and suppress ferroptosis, while inhibiting STAT3 phosphorylation, reducing pro-inflammatory cytokines, and modulating xCT/GPX4 expression. In HRMECs, NRF2 inhibition or STAT3 activation attenuated CGA's protective effects, highlighting the critical roles of these pathways. Molecular docking and CETSA analyses further identified N485 of STAT3 as a key residue mediating CGA binding and functional regulation. These findings indicate that CGA exerts multi-modal protective effects against DR by targeting oxidative stress, ferroptosis, and inflammation. This study provides mechanistic insight into CGA as a potential therapeutic candidate for T2D-associated retinal complications and underscores the broader relevance of NRF2 and STAT3 pathways as intervention targets in diabetes-related microvascular disorders.
Indexed as
Identifiers
41729256What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.